3-deazaneplanocin has been researched along with T-Cell Lymphoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bi, C; Chng, WJ; Choo, SN; Huang, G; Koh, TL; Lin, B; Liu, SC; Ng, SB; Selvarajan, V; Shimizu, N; Tan, J; Tay, JL; Wang, S; Yan, J; Yu, Q | 1 |
1 other study(ies) available for 3-deazaneplanocin and T-Cell Lymphoma
Article | Year |
---|---|
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Enhancer of Zeste Homolog 2 Protein; Female; Gene Expression Regulation, Neoplastic; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Killer Cells, Natural; Lymphoma, T-Cell; Male; MicroRNAs; Middle Aged; Mutagenesis; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Up-Regulation; Young Adult | 2013 |